prikaz prve stranice dokumenta NUSPOJAVE BIOLOŠKE TERAPIJE U BOLESNIKA S UPALNIM BOLESTIMA CRIJEVA
Access restricted to students and staff of home institution
master's thesis
NUSPOJAVE BIOLOŠKE TERAPIJE U BOLESNIKA S UPALNIM BOLESTIMA CRIJEVA
Rijeka: University of Rijeka, Faculty of Health Studies, 2019. urn:nbn:hr:184:023628
Grahovac, Anka
University of Rijeka
Faculty of Health Studies
Department of Midwifery

Institutional repository: Repository of the University of Rijeka, Faculty of Health Studies

Cite this document

Grahovac, A. (2019). NUSPOJAVE BIOLOŠKE TERAPIJE U BOLESNIKA S UPALNIM BOLESTIMA CRIJEVA (Master's thesis). Rijeka: University of Rijeka, Faculty of Health Studies. Retrieved from https://urn.nsk.hr/urn:nbn:hr:184:023628

Grahovac, Anka. "NUSPOJAVE BIOLOŠKE TERAPIJE U BOLESNIKA S UPALNIM BOLESTIMA CRIJEVA." Master's thesis, University of Rijeka, Faculty of Health Studies, 2019. https://urn.nsk.hr/urn:nbn:hr:184:023628

Grahovac, Anka. "NUSPOJAVE BIOLOŠKE TERAPIJE U BOLESNIKA S UPALNIM BOLESTIMA CRIJEVA." Master's thesis, University of Rijeka, Faculty of Health Studies, 2019. https://urn.nsk.hr/urn:nbn:hr:184:023628

Grahovac, A. (2019). 'NUSPOJAVE BIOLOŠKE TERAPIJE U BOLESNIKA S UPALNIM BOLESTIMA CRIJEVA', Master's thesis, University of Rijeka, Faculty of Health Studies, accessed 07 November 2024, https://urn.nsk.hr/urn:nbn:hr:184:023628

Grahovac A. NUSPOJAVE BIOLOŠKE TERAPIJE U BOLESNIKA S UPALNIM BOLESTIMA CRIJEVA [Master's thesis]. Rijeka: University of Rijeka, Faculty of Health Studies; 2019 [cited 2024 November 07] Available at: https://urn.nsk.hr/urn:nbn:hr:184:023628

A. Grahovac, "NUSPOJAVE BIOLOŠKE TERAPIJE U BOLESNIKA S UPALNIM BOLESTIMA CRIJEVA", Master's thesis, University of Rijeka, Faculty of Health Studies, Rijeka, 2019. Available at: https://urn.nsk.hr/urn:nbn:hr:184:023628

Metadata
TitleNUSPOJAVE BIOLOŠKE TERAPIJE U BOLESNIKA S UPALNIM BOLESTIMA CRIJEVA
Title (english)ADVERSE EFFECTS OF BIOLOGICAL THERAPY IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES
AuthorAnka Grahovac
MentorBrankica Mijandrušić-Sinčić (mentor)
Committee memberSandra Milić (predsjednik povjerenstva)
GranterUniversity of Rijeka
Faculty of Health Studies
(Department of Midwifery)
Rijeka
Defense date and country2019-09-18, Croatia
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Internal Medicine
Abstract
U upalne bolesti crijeva pripadaju Crohnova bolest i ulcerozni kolitis. Uz kronične upalne promjene mogu biti pridružene i izvancrijevne manifestacije bolesti. Etiologija bolesti je nepoznata, a u patogenezi sudjeluju vanjski čimbenici rizika, genetska predispozicija i narušenost imunološkog sustava. Dijagnoza upalnih bolesti crijeva se temelji na kombinaciji anamneze, laboratorijskih nalaza, endoskopskih pretraga s uzimanjem uzoraka za patohistološku analizu te radiološkim pretragama. Upalne bolesti se liječe aminosalicilatima, kortikosteroidima, imunomodulatorima, antibioticima te biološkom terapijom. Pravovremena primjena biološke terapije može zaustaviti napredovanje upalnih procesa, spriječiti komplikacije i nastanak invaliditeta. Prije uvođenja imunosupresivne i biološke terapije potrebno je učiniti probir na oportunističke infekcije. Svi navedeni lijekovi mogu uzrokovati nuspojave koje mogu varirati po učestalosti i težini. Cilj našeg rada je bio utvrditi nuspoajave biološke terapije. Retrospektivno smo analizirali 145 boelsnika koji su se liječili u dnevnoj bolnici interne klinike KBC u Rijeci u razdoblju od 1. siječnja 2010. do 30. lipnja 2019. godine. Najučestalije je apliciran infliksimab, potom adalimumab, vedolizumab zatim ustekinumab i golimumab. Prosječno trajanje terapije za sve bolesnike je 17 mjeseci. Na ukupan broj apliciranih terapija, u 127 slučajeva je opisana barem jedna nuspojava lijeka. Nuspojave smo podijelili u četiri kategorije, i to: neučinkovitost terapije, teža alergijska reakcija, teška infektivna komplikacija, maligna bolest te ostale nuspojave. Najučestalija nuspojava i razlog za prekid terapije je bila neučinkovitost lijeka. Potom slijede teže nuspojave redom: alergija, infekcija i maligna bolest. Učestalost ispitivanih nuspojava nije statistički značajna s obzirom na dijagnozu. Zaključno možemo reći da se rezultati ovog istraživanja uglavnom podudaraju s rezultatima iz literature, no potrebna su daljnja istraživanja.
Abstract (english)
Inflammatory bowel diseases are Crohn's disease and ulcerative colitis. These are chronic diseases, usually presenting with gastrointestinal symptoms, and in some cases, extraintestinal manifestations. Etiology is unknown. Pathogenesis is believed to be mostly influenced by external risk factors, genetic predisposition and immunologic abnormalities. Diagnosis is based on symptoms, laboratory testing, radiological findings and endoscopic confirmation - patohistological analysis of biopsy material. Treatment comprises of aminosalicylates, corticosteroids, immunomodulators and biologic therapy. Prior to introducing biologic therapy, one must perform screening tests for various latent viral disease, neurological and general medical check-up. The goal of this thesis was to ascertain adverse effects of biological therapy. Retrospectively, we peformed analysis on 145 of our patients from our University Hospital Centre in Rijeka, in the period between 2010. to 2019. Infliximab was most commonly prescribed medication, followed by adalimumab, vedolizumab, ustekinumab and golimumab. Average duration of therapy was 17 months. We've had a total of 127 cases of documented adverse effects. We divided them in 4 groups: inefficacy, alergic reaction, severe infectious complication and malignant disease. Most common side effect was inefficacy, followed by alergy, infection and malignant tumour. Frequency of mentioned adverse effects was mild and moderate compared to benefits of biologic therapy and disease control. Lastly, findings of our paper are in in sync with other current literature on this matter.
Keywords
Keywords (english)
Languagecroatian
URN:NBNurn:nbn:hr:184:023628
Study programmeTitle: Graduate university study of Nursing: Healthcare Management (Biomedicine and Healthcare; clinical medical sciences)
Study programme type: university
Study level: graduate
Academic / professional title: magistar/magistra sestrinstva (magistar/magistra sestrinstva)
Type of resourceText
File originBorn digital
Access conditionsAccess restricted to students and staff of home institution
Terms of useLicence In copyright icon
Created on2019-11-14 10:55:59